Trends in checkpoint inhibitor therapy for advanced urothelial cell carcinoma (aUC) at the end of life: Insights from real-world practice.
Parikh R, Galsky M, Gyawali B, Riaz F, Kaufmann T, Cohen A, Adamson B, Gross C, Meropol N, Mamtani R. Trends in checkpoint inhibitor therapy for advanced urothelial cell carcinoma (aUC) at the end of life: Insights from real-world practice. Journal Of Clinical Oncology 2019, 37: 395-395. DOI: 10.1200/jco.2019.37.7_suppl.395.Peer-Reviewed Original ResearchAdvanced urothelial cell carcinomaPoor performance statusEnd of lifeSystemic therapyDay of deathQuarterly proportionPoor PSStudy periodFlatiron Health databaseSystemic therapy initiationCheckpoint inhibitor therapyFavorable toxicity profileUrothelial cell carcinomaDays of lifeSecular trend analysisChemotherapy initiationChemotherapy useCPI useReal-world practiceTherapy initiationInhibitor therapyPerformance statusPS 0Cell carcinomaNational guidelines